Summary:
To evaluate the efficacy, safety and tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the acute treatment of a migraine.
Qualified Participants Must:
• Be at least 18 years of age
•
Experience at least 2 migraines per month over the last 6 months
Qualified Participants May Receive:
- Study related procedures such as blood work and ECG
- Compensation for time and travel expenses
- Physical performed by a board certified physician